Aug 20, 2025 8:30am EDT Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Aug 13, 2025 4:20pm EDT Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Aug 05, 2025 8:10am EDT Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
May 29, 2025 8:30am EDT Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
May 13, 2025 4:30pm EDT Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
May 07, 2025 8:30am EDT Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
Apr 16, 2025 8:30am EDT Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
Apr 15, 2025 8:30am EDT Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity